Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen cascade impactor and the next generation pharmaceutical impactor

Journal of Pharmaceutical Sciences

Volumn 97, Issue 8, 2008, Pages 3321-3334

  Guo, Changning ^a   Gillespie, Stacey R ^a,b   Kauffman, John ^a   Doub, William H ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b KENNEDY SPACE CENTER   (United States)

Author keywords

Albuterol sulfate; Andersen cascade impactor; Combivent ; Dose delivery profile; Flow rate; Induction port; Ipratropium bromide; Next generation pharmaceutical impactor; Particle size distribution

Indexed keywords

IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALBUTAMOL SULFATE;

AIRFLOW; ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METERED DOSE INHALER; PARTICLE SIZE;

EID: 52449105891     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21203     Document Type: Article

References (34)

1. BTS and SIGN. 2003. British guideline on the management of asthma. Thorax 58:11-94.
2. Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, Calverley PMA, Chavannes N, Dillard T, Fahy B, Fein A, Heffner J, Lareau S, Meek P, Martinez F, McNicholas W, Muris J, Austegard E, Pauwels R, Rennard S, Rossi A, Siafakas N, Piep B, Vestbo J, Wouters E, ZuWallack R. 2004. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 23:932-946.
3. June DS, Schultz RK, Miller NC. 1994. A conceptual model for the development of pressurized metered-dose hydrofluroalkane-based inhalation aerosols. Pharm Tech 18:40-52.
4. Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Oort MV, Olsson B, Holroyd MJ, Mitchell JP, Hochrainer D. 2003. Next Generation Pharmaceutical Impactor (A New Impactor for Pharmaceutical Inhaler Testing). Part I: Design. J Aerosol Med 16:283-299.
5. Andersen AA. 1958. New sampler for the collection, sizing, and enumeration of viable airborne particles. J Bacteriol 76:471-484.
6. Holzner PM, Muller BW. 1995. Particle size determination of metered dose inhalers with inertial separation methods: Apparatus A and B (BP), Four Stage Impinger and Andersen Mark II Cascade Impactor. Int J Pharm 116:11-18.
7. Division of Pharmaceutical Analysis, U.S. Food and Drug Administration. Study 03T, Comparison of the Next Generation Pharmaceutical Impactor To the Andersen Cascade Impactor, by Rudolph Kulousek, William H. Doub, Anna M. Wokovich (unpublished results).
8. Taki M, Zeng X, Marriott C, Martin G. 2006. Comparison of deposition profiles of drugs from a combination dry powder inhaler using the Anderson Cascade Impactor (ACI), Multistage Liquid Impinger (MSLI), and Next Generation Impactor (NGI). In: RN, Dalby PR, Byron J, Peart JD, Suman Farr SJ, editors. Respiratory drug delivery 2006. River Grove, IL: Davis Healthcare International Publishing, pp 659-662.
9. Kamiya A, Sakagami M, Hindle M, Byron PR. 2003. Particle sizing with the Next Generation Impactor: A Study Of Vanceril™ Metered Dose Inhaler. J Aerosol Med 16:216.
10. Kamiya A, Sakagami M, Hindle M, Byron PR. 2004. Aerodynamic sizing of metered dose inhalers: An evaluation of the Andersen and Next Generation Pharmaceutical Impactors and their USP methods. J Pharm Sci 93:1828-1837.
11. Mitchell JP, Nagel MW, Wiersema KJ, Doyle CC. 2003. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: Comparison of Anderson 8-Stage Cascade Impactor, Next Generation Pharmaceutical Impactor, and Model 3321 Aerodynamic Particle Sizer Aerosol Spectrometer. AAPS Pharm Sci Tech 4:54.
12. Hinds WC. 1986. Data analysis, Chapter 3. In: Lodge JP, Chan LT, editors. Cascade impactor: Sampling & Data Analysis. Akron, OH: American Industrial Hygiene Association, pp 45-78.
13. Lippmann M, Albert RE. 1969. The effect of particle size on the regional deposition of inhaled aerosols in the human respiratory tract. Am Ind Hyg Assoc J 30:257-275.
14. Lippmann M. 1977. Regional deposition of particles in the human respiratory tract. In: Lee DHK, editor. Handbook of physiology - Section 9: Reaction to environmental agents. Bethesda, MD: American Physiology Society. pp 213-232.
15. Foord N, Black A, Walsh M. 1978. Regional deposition of 2.5-7:5 μm diameter inhaled particles in healthy male non-smokers. J Aerosol Sci 9:343-357.
16. Chan LT, Lippmann M. 1980. Experimental measurements and empirical modelling of the regional deposition of inhaled particles in humans. Am Ind Hyg Assoc J 41:399-409.
17. Emmett CP, Aitken JR, Hannan WJ. 1982. Measurements of the total and regional deposition of inhaled particles in the human respiratory tract. J Aerosol Sci 13:549-560.
18. Stahlhofen W, Gebhard J, Heyder J. 1980. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J 41:385-398.
19. Stahlhofen W, Gebhard J, Heyder J. 1981. Biological variability of regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J 42:348-352.
20. Stahlhofen W, Gebhard J, Heyder J, Scheuch G. 1983. New regional deposition data of the human respiratory tract. J Aerosol Sci 14:186-188.
21. Stahlhofen W, Gebhard J, Heyder J, Scheuch G, Juraske P. 1984. Particle deposition in extrathoracic airways of healthy subjects and of patients with early stages of laringeal carcinoma. J Aerosol Sci 15:115-117.
22. Svartengren K, Lindestad AP, Svartengren M, Bylin G, Philipson G, Camner P. 1994. Deposition of inhaled particles in the mouth and throat of asthmatic subjects. Eur Respir J 7:1467-1473.
23. Svartengren K, Lindestad AP, Svartengren M, Philipson G, Bylin G, Camner P. 1995. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med 152:32-37.
24. Borgstrom L. 1999. In vitro, in vivo, ex vivo veritas. Allergy 54:88-92.
25. Swift LD. 1992. Apparatus and method for measuring regional distribution of therapeutic aerosols and comparing delivery systems. J Aerosol Sci 23: 495-198.
26. Cheng KH, Cheng TS, Yeh HC, Swift DL. 1997. An experimental method for measuring aerosol deposition efficiency in the human oral airway. Am Ind Hyg Assoc J 58:207-213.
27. Cheng KH, Cheng TS, Yeh HC, Swift DL. 1997. Measurement of airway dimensions and calculation of mass transfer characteristics of the human oral passage. J Biomed Eng 119:475-482.
28. Cheng YS, Zhou Y, Chen TB. 1999. Particle deposition in a cast of human oral airways. Aerosol Sci Technol 31:286-300.
29. Cheng YS, Fu CS, Yazzie D, Zhou Y. 2001. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med 14:255-266.
30. Lin CT, Breysse PN, Beth LL, Swift DL. 2001. Mouthpiece diameter affects deposition efficiency in cast models of the human oral airways. J Aerosol Med 14:335-341.
31. Grgica B, Finlaya WH, Burnellb PKP, Heenanb AF. 2004. In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries. Aerosol Sci 35:1025-1040.
32. Clark AR. 1991. Metered Atomisation for Respiratory Drug Delivery. PhD Thesis for Department of Mechanical Engineering Loughborough University, Loughboro, UK.
33. Clark AR. 1992. The physics of aerosol formation by MDIs - Limitations of the current approach. J Biopharm Sci 3:69-76.
34. Taki M, Zeng X, Marriott C, Martin G. 2006. An assessment of the in vitro deposition of aerosolized drugs from a combination dry powder inhaler using the Anderson cascade impactor (ACI). In: RN, Dalby PR, Byron J, Peart JD, Suman Farr SJ, editors. Respiratory drug delivery 2006. River Grove, IL: Davis Healthcare International Publishing, pp 655-658.